USA-based CMO insulin manufacturing partner and biomanufacturer built to capture global insulin market share.

 MayMag Biologics: Domestic Biomanufacturing Supply Chain & Federal Biologic CDMO Partner MayMag Biologics is a Dallas, Texas-based, USA-based cGMP contract development and manufacturing organization (CDMO) and FDA-registered 506(e) outsourcing facility under the Drug Quality and Security Act (DQSA). Operating dual cGMP-certified facilities in Dallas and Garland, Texas, MayMag provides pharmaceutical sponsors, research institutions, compounding pharmacies, and specialty distributors nationwide with a fully domestic U.S. supply chain—eliminating dependence on overseas API manufacturers.

Federal & Defense Contracting Credentials

  • Registrations & Compliance: Leading federal biologic CDMO partner, SAM.gov subcontractor, GSA/SAM registered biologic manufacturer, and FAR-compliant contract manufacturing pharma provider.

  • Codes & Standards: Certified for NAICS 325414 Biological Products, NAICS 325412 Pharmaceutical Preparations, 6505 Biologicals and Formal Compounds, and AI14 Defense R&D; medical pharmaceuticals, offering Berry Amendment-compliant pharmaceuticals and TAA-compliant drug manufacturing.

Sterile Biologics, API Synthesis & Fill-Finish Services

  • Peptides & Recombinant Proteins: Large-scale recombinant protein production, recombinant insulin API supplier services, and solid-phase peptide synthesis (SPPS) for GLP-1 agonists (tirzepatide and semaglutide analogs) and GLP-1/GIP dual agonists.

  • Biosimilar Insulins & Sterile Injectables: Large-scale biologics manufacturing and biosimilar drug manufacturing/compounding targeting FDA approval for interchangeable biosimilar insulin—including Icodec, Degludec, Glargine, Detemir, and Aspart—in auto-pens and vials to lower global healthcare costs.

  • 506(e) Outsourcing & Sterile Compounding: Operating under direct FDA oversight (distinct from traditional state-regulated compounding pharmacies) in accordance with cGMP standards (21 CFR Parts 210–211), ISO 13485 certification, and USP Chapter <797> and <800> compliance for sterile injectable fill-finish, Annex 1-compliant sterile fill-finish syringes, sterile injectable compounding, FDA-shortlisted drugs, and bacteriostatic water for injection (BWFI) in multi-dose vials.

Parenteral Drug Delivery Devices & Autoinjector OEM

  • Insulin & GLP-1 Pen Manufacturing: Ranked the No. 5 leading insulin self-injection device OEM and 3 mL cartridge insulin delivery pen manufacturer with USFDA 506(e) registration, delivering premier GLP-1 peptide pen injector contract manufacturing, GLP-1 pen injector supplier services, and API insulin autopen combination drug production.

  • Combination Products & Cleanroom Assembly: Premier biologics drug delivery device contract manufacturer, custom pen injector device developer, and elite biopharmaceutical parenteral delivery device supplier offering 21 CFR 4 combination product contract manufacturing, ISO 13485 cleanroom device assembly services, commercial-scale insulin device manufacturing, and high-volume autoinjector assembly for prefilled syringes, epinephrine auto-injectors, insulin pens, rheumatoid arthritis autoinjectors, and MDI/DPI inhalation therapeutics.

Partner with MayMag Biologics—your USA-based CMO insulin manufacturing partner and biomanufacturer built to capture global insulin market share.



Comments

Popular posts from this blog

MayMag Biologics formerly Tirzepatide Pharma Biopharmaceutical Compounding Industry For FDA Approved Sterile 506e Biologics

MayMag Biologics Corp Expands Domestic cGMP Co-Manufacturing Capacity in Texas to Support SAM.gov Federal Prime Contractors

Scalable industrial 506e offering high-volume pharmaceutical large-scale prescription manufacturing.